sdx8 Posted - 11 hours ago

$SAGE someone dumped today? Or more manipulation?

sdx8 Posted - 04/30/24

$SAGE low volume today

klr500 Posted - 04/29/24

$SAGE 👀

AnaChart Posted - 04/26/24

$SAGE https://anachart.com/wp-content/uploads/ana_temp/1714147360_soc-img.jpg

sdx8 Posted - 04/26/24

$SAGE BIIB invested 1.5B already , can acquire $3-3.5B - cash and shares they own. Insiders own 13% hope they agree to buyout.

mcdicedtea Posted - 04/26/24

$SAGE Greene, sell the company now to BIIB for $3B. That's only 2.25B after cash. You'll never see $50 again if you GIA. The stock went from 100's to 11. You need to act now before it's too late.

junov239 Posted - 04/25/24

$SAGE let me get a fade + way

junov239 Posted - 04/25/24

$SAGE lets see $12s again

junov239 Posted - 04/25/24

$SAGE it will fade away…just give it some time

mcdicedtea Posted - 04/25/24

$SAGE quiet board. thoughts on ER??? BIIB needs to buy them out or take over more of the day to day activities. Don't think mgt at SAGE can get it done based on the last 3 years of work.

GansoManso Posted - 04/25/24

$SAGE Yeah... what a surprise.

DonCorleone77 Posted - 04/25/24

$SAGE Sage Therapeutics reports Q1 EPS ($1.80), consensus ($1.65) Reports Q1 revenue $7.9M, consensus $5.66M. "The launch of ZURZUVAE is off to an encouraging start, reflected in the strong performance in the first full quarter of the launch. We are seeing increasing demand among HCPs, particularly OBGYNs, and hearing inspiring success stories from women with PPD treated with ZURZUVAE. Importantly, momentum in commercial and government payor coverage is helping to support our goal of broad and equitable access for women with PPD," said CEO Barry Greene. "In parallel, we are working with urgency to advance efforts across our pipeline. While we are disappointed by the results of the Phase 2 PRECEDENT study given the significant burden of mild cognitive impairment on people and families affected by Parkinson's Disease, we look forward to the other data readouts for dalzanemdor and SAGE-324 expected in 2024."

sdx8 Posted - 04/25/24

$SAGE short interest up to 23% now

epsguid Posted - 04/25/24

$SAGE reported a loss of $1.80, consensus was ($1.63) via @eWhispers #epsmiss http://eps.sh/d/sage

Stock_Titan Posted - 04/25/24

$SAGE Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress https://www.stocktitan.net/news/SAGE/sage-therapeutics-announces-first-quarter-2024-financial-results-and-5j893q17bc6n.html

sdx8 Posted - 04/24/24

$SAGE hope we get positive unexpected news + earnings beat. This was steadily in $20s.

sdx8 Posted - 04/24/24

$SAGE 2.3 m volume. Right before earnings

WhiteKnuckleInvestments Posted - 04/24/24

$SAGE ZURZUVAE delivered $12 million of revenue in Q1. If total sales were $24 million for Q1 (split 50/50), it is over achieving to date.

WhiteKnuckleInvestments Posted - 04/24/24

$SAGE Part II: Two of the three national pharmacy benefit managers are providing coverage for ZURZUVAE without overly burdensome restrictions. We are in active discussions with the third national PBM as we await their decision. And while Medicaid tends to take longer, almost half of the states, including several of the largest, accelerated reviews into quarter one, which we believe is unusual for a process that can typically take-up to a year after FDA approval. We are encouraged that approximately two-thirds of Medicaid lives with published policies appear to have minimal access restrictions. We anticipate the remaining states will review coverage throughout 2024, and we will continue to support their reviews as much as possible.

WhiteKnuckleInvestments Posted - 04/24/24

$SAGE Some color on Biogen Q1 call: ZURZUVAE. As Chris mentioned, we are encouraged by the performance of the launch to date, and we think we are seeing several positive trends with providers, patient experience, and reimbursement. First, let me begin with providers. Across multiple physician types, we believe many providers are demonstrating an urgency to treat. Notably, OB-GYNs led overall prescribing in quarter one, which we believe is encouraging as they are often the first to see PPD patients. Furthermore, breadth of adoption has continued to grow. In March, nearly double the number of HCPs prescribed ZURZUVAE compared to just January. We've seen that some early prescribers require only a few calls before they treat. Keep in mind that ZURZUVAE is a scheduled product available through a specialty pharmacy. While we believe psychiatrists are generally familiar with working with specialty pharmacy, this could be a new process for many OB-GYNs. *Expect Barry to adopt similar language*

Letsrollup Posted - 04/24/24

$SAGE

sdx8 Posted - 04/24/24

$SAGE I’m hoping tomorrow they announce with BIIB support to continue MDD. This will shoot over $20

IsabellaDC Posted - 04/24/24

Spat out by a scan. Name the name of the scan. $AFYA $EPIX $INTC $SAGE $INVZ

OCStockDoc Posted - 04/24/24

$SAGE Is this MDD trial ongoing? https://classic.clinicaltrials.gov/ct2/show/NCT05655507?term=Sage+217&draw=3&rank=14

sdx8 Posted - 04/24/24

$SAGE come on buyout!!!

junov239 Posted - 04/24/24

$SAGE back to $12

Justy_Nuff Posted - 04/24/24

$SAGE someone gobbled up 500k shares. Like $GCTS too

Letsrollup Posted - 04/24/24

$SAGE

HorizonBull Posted - 04/24/24

$SAGE short in control

WhiteKnuckleInvestments Posted - 04/24/24

$SAGE More to come on Biogen’s CC. No breakout of sales but this was enough of a catalyst this morning. ZURZUVAE launch shows encouraging early trends Reminder, they split revenue 50/50 with Biogen.